Trial watch: IL-13 antibody enhances breathing in bronchial asthma
Character Reviews Drug Discovery 10, 722 (2011).
doi:10.1038/nrd3562
Is a result of a Phase II medical trial of lebrikizumab (N. Engl. J. Mediterranean. 3 August 2011 doi:10.1056/NEJMoa1106469), a humanized monoclonal antibody that targets interleukin-13 (IL-13), have proven the biologic enhances breathing in grown ups with out of control bronchial asthma.Girolamo Pelaia, (Source: Character Reviews Drug Discovery) More details: Read more...